Altamira Therapeutics Ltd. [NASDAQ: CYTO] traded at a high on 04/18/23, posting a 8.18 gain after which it closed the day’ session at $1.19. The company report on April 12, 2023 that Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed Journal.
Detailed results from TRAVERS trial addressing acute vestibular syndrome with AM-125 (intranasal betahistine) published in Otology & Neurotology.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
The results of the trading session contributed to over 8708437 shares changing hands. Over the past one week, the price volatility of Altamira Therapeutics Ltd. stands at 43.17% while the volatility over the past one month is 24.98%.
The market cap for CYTO stock reached $1.69 million, with 1.17 million shares outstanding and 1.09 million shares in the current float. Compared to the average trading volume of 1.64M shares, CYTO reached a trading volume of 8708437 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Altamira Therapeutics Ltd. [CYTO]?
The Average True Range (ATR) for Altamira Therapeutics Ltd. is set at 0.41, with the Price to Sales ratio for CYTO stock in the period of the last 12 months amounting to 1.21. The Price to Book ratio for the last quarter was 0.11, with the Price to Cash per share for the same quarter was set at 0.28.
How has CYTO stock performed recently?
Altamira Therapeutics Ltd. [CYTO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.85. With this latest performance, CYTO shares dropped by -11.85% in over the last four-week period, additionally sinking by -79.84% over the last 6 months – not to mention a drop of -94.22% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CYTO stock in for the last two-week period is set at 43.39, with the RSI for the last a single of trading hit 43.69, and the three-weeks RSI is set at 42.18 for Altamira Therapeutics Ltd. [CYTO]. The present Moving Average for the last 50 days of trading for this stock 1.8800, while it was recorded at 1.3700 for the last single week of trading, and 5.4585 for the last 200 days.
Altamira Therapeutics Ltd. [CYTO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Altamira Therapeutics Ltd. [CYTO] shares currently have an operating margin of -25094.04 and a Gross Margin at -3526.86. Altamira Therapeutics Ltd.’s Net Margin is presently recorded at -27222.33.
Return on Total Capital for CYTO is now -102.72, given the latest momentum, and Return on Invested Capital for the company is -113.82. Return on Equity for this stock declined to -115.58, with Return on Assets sitting at -86.06. When it comes to the capital structure of this company, Altamira Therapeutics Ltd. [CYTO] has a Total Debt to Total Equity ratio set at 4.53. Additionally, CYTO Total Debt to Total Capital is recorded at 4.34, with Total Debt to Total Assets ending up at 3.06. Long-Term Debt to Equity for the company is recorded at 3.63, with the Long-Term Debt to Total Capital now at 3.47.
Reflecting on the efficiency of the workforce at the company, Altamira Therapeutics Ltd. [CYTO] managed to generate an average of -$1,118,876 per employee. Receivables Turnover for the company is 0.13 with a Total Asset Turnover recorded at a value of 0.00.Altamira Therapeutics Ltd.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.20 and a Current Ratio set at 0.20.
Insider trade positions for Altamira Therapeutics Ltd. [CYTO]
There are presently around $0 million, or 1.90% of CYTO stock, in the hands of institutional investors. The top three institutional holders of CYTO stocks are: UBS GROUP AG with ownership of 3,847, which is approximately 845.209% of the company’s market cap and around 7.10% of the total institutional ownership; MORGAN STANLEY, holding 2,495 shares of the stock with an approximate value of $3000.0 in CYTO stocks shares; and GROUP ONE TRADING, L.P., currently with $1000.0 in CYTO stock with ownership of nearly -76.906% of the company’s market capitalization.
Positions in Altamira Therapeutics Ltd. stocks held by institutional investors increased at the end of Tuesday and at the time of the Tuesday reporting period, where 1 institutional holders increased their position in Altamira Therapeutics Ltd. [NASDAQ:CYTO] by around 3,440 shares. Additionally, 11 investors decreased positions by around 17,214 shares, while 2 investors held positions by with 13,509 shares. The mentioned changes placed institutional holdings at 7,145 shares, according to the latest SEC report filing. CYTO stock had 0 new institutional investments in for a total of 0 shares, while 7 institutional investors sold positions of 14,135 shares during the same period.